Capital Advisors Ltd’s Cartesian Therapeutics RNAC Stock Holding History

Capital Advisors Ltd’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5	Closed	–	–	1579
2024 Q2	$0	Buy	5 +2	+67%	+$48	﹤0.01%	1609
2024 Q1	$0	Buy	+3	New	+$64	﹤0.01%	1519

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Advisors Ltd's RNAC Position: Q3 2024 in Review

Capital Advisors Ltd sold out of Cartesian Therapeutics (RNAC) in Q3 2024, closing a stake of 5 shares.

Capital Advisors Ltd first reported a position in RNAC in Q1 2024 and held it in 2 quarters. The position peaked at $0 in Q2 2024. 64 funds tracked by Wall St. Rank hold RNAC as of Q3 2024.

Capital Advisors Ltd reported no remaining Cartesian Therapeutics position as of Q3 2024 after selling out during the quarter.
Capital Advisors Ltd sold 5 Cartesian Therapeutics shares in Q3 2024.
Capital Advisors Ltd first reported a position in Cartesian Therapeutics in Q1 2024 and held it in 2 quarters.
Capital Advisors Ltd's Cartesian Therapeutics position peaked at $0 in Q2 2024.
64 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2024.

Based on Capital Advisors Ltd's 13F filing for Q3 2024, filed 24 Oct 2024.